Header Logo

WALLIS MOLCHEN

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address6621 FANNIN
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    2023Department of Pediatrics Outstanding Clinician Award, Baylor College of Medicine
    2024Early Career Faculty Award for Excellence in Patient Care, Baylor College of Medicine

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. . Impact of EHR on Realism, Skills, and Workload in Sepsis Simulation. Clinical Simulation in Nursing. 2024; 93(101560). View Publication.
    2. Acorda DE, Jackson A, Lam AK, Molchen W. Overwhelmed to ownership: The lived experience of parents learning to become caregivers of children with tracheostomies. Int J Pediatr Otorhinolaryngol. 2022 Dec; 163:111364. PMID: 36330951.
      Citations:    Fields:    
    3. Nicome R, Lo HY, Gupta S, Khan A, Lee A, Molchen W, Neubauer H, Ramgopal V, Lyn M, Weber E, Vachani J. Utilizing a Behavioral Health Bundle to Improve Patient and Clinician Safety for Hospitalized Children. Pediatr Qual Saf. 2021 Mar-Apr; 6(2):e393. PMID: 33718748; PMCID: PMC7952108.
      Citations:    
    4. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT, HALT-C Trial Group. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144. PMID: 22359532; PMCID: PMC3281016.
      Citations:    
    5. Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ, HALT-C Trial group. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011 Dec; 21(12):851-60. PMID: 21946897; PMCID: PMC3215092.
      Citations:    
    6. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS, HALT-C Trial Group. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54(5):1527-37. PMID: 22045670; PMCID: PMC3718548.
      Citations:    
    7. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug; 54(2):434-42. PMID: 21374690; PMCID: PMC3134544.
      Citations:    
    8. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM, HALT-C Trial Group. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011; 6(7):e20904. PMID: 21760886; PMCID: PMC3132753.
      Citations:    
    9. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE, HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405. PMID: 21520194; PMCID: PMC3144992.
      Citations:    
    10. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG, HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8. PMID: 21480316; PMCID: PMC3073857.
      Citations:    
    11. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT, HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141(1):141-9. PMID: 21440548; PMCID: PMC3129453.
      Citations:    
    12. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE, HALT-C TRIAL GROUP. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun; 140(7):1961-9. PMID: 21376050; PMCID: PMC3109110.
      Citations:    
    13. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL, HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May; 140(5):1490-500.e3. PMID: 21335007; PMCID: PMC3081953.
      Citations:    
    14. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL, HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9. PMID: 20675691; PMCID: PMC3740000.
      Citations:    
    15. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR, HALT-C Trial Group. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010 Mar-Apr; 51(2):137-48. PMID: 20332289; PMCID: PMC3746312.
      Citations:    
    16. Bell MC, Robuck PR, Wright EC, Mihova MS, Hofmann C, De Santo JL, Milstein SL, Richtmyer PA, Shelton JL, Cormier M, King DL, Park CJ, Molchen WA, Park Y, Kelley M. Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Trials. 2009 Dec; 6(6):618-27. PMID: 19889888; PMCID: PMC3753781.
      Citations: 1     Fields:    Translation:Humans
    17. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R, HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9. PMID: 19676128; PMCID: PMC2783828.
      Citations:    
    18. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C, HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37. PMID: 19291787; PMCID: PMC2692566.
      Citations:    
    19. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR, HALT-C Trial Group. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58. PMID: 19434718; PMCID: PMC2692559.
      Citations:    
    20. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL, Halt-C Trial Group. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26. PMID: 19068241; PMCID: PMC3766729.
      Citations:    
    21. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48. PMID: 18848939; PMCID: PMC3749922.
      Citations:    
    22. Jaber O, Sehgal CJ, Swamy P, Holzmann-Pazgal G, Acosta E, Aririguzo L, Rueda A, Benjamin J, Kim J, Wood M, Tatem A, MOLCHEN W, Das S. Infectious Diseases. In: Cabana MD, Giardino AP. eds. Rudolph's Pediatrics, 23e, Self-Assessment and Board Review. McGraw Hill; 2021. View Publication.
    23. Sehgal CJ, Rueda A, Acosta E, Benjamin J, Aririguzo L, Kim J, Lambert E, MOLCHEN W, Tatem A, Wood M, Burge SD. Ear, Eye, Nose, and Throat. In: Cabana MD, Giardino AP. eds. Rudolph's Pediatrics, 23e, Self-Assessment and Board Review. McGraw Hill; 2021. View Publication.
    MOLCHEN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (96)
    Explore
    _
    Co-Authors (7)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _